Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)

Q: What did Elanco (NYSE: ELAN) announce about Credelio Quattro on July 22, 2026?

Elanco announced new peer-reviewed data showing Credelio Quattro kills ticks faster than Simparica Trio and NexGard Plus. According to Elanco, it achieved significant black-legged tick reduction within 8 hours and maintained this rapid effect through Day 28, covering the full monthly dosing interval.

Q: How fast does Credelio Quattro kill ticks compared with Simparica Trio and NexGard Plus (ELAN)?

Credelio Quattro significantly reduces black-legged ticks within 8 hours, versus 12–24 hours for competitors. According to Elanco, this 8-hour speed of kill is maintained on Day 0 and Day 28, while Simparica Trio and NexGard Plus show slower and declining performance later in the month.

Q: Does Credelio Quattro (ELAN) protect dogs against Lyme disease?

Yes, Credelio Quattro has an FDA-approved claim for prevention of Lyme disease infections in dogs. According to Elanco, this is achieved as a direct result of killing black-legged ticks, the primary vector of Borrelia burgdorferi, over the one-month dosing interval.

Q: What are the main safety concerns for Credelio Quattro mentioned by Elanco (NYSE: ELAN)?

Credelio Quattro’s isoxazoline component has been associated with neurologic reactions, including tremors, incoordination, and seizures. According to Elanco, vomiting and diarrhea were the most frequent adverse reactions, and caution is advised in dogs with seizure or neurologic histories and in untested heartworm-positive dogs.

Q: What parasites does Credelio Quattro treat and prevent for dogs (ticker ELAN)?

Credelio Quattro prevents heartworm disease and treats or controls roundworms, hookworms, tapeworms, fleas, and ticks for one month. According to Elanco, it also carries an FDA-approved indication for preventing Lyme disease infections through killing black-legged ticks in dogs 8 weeks and older, 3.3 pounds or greater.

Q: How effective is lotilaner against lone star ticks compared with sarolaner and afoxolaner?

Lotilaner, used in Credelio and Credelio Quattro, achieves the fastest initial lone star tick kill in 12 hours. According to Elanco, head-to-head studies showed lotilaner killed lone star ticks faster than sarolaner in Simparica Trio and afoxolaner in NexGard, maintaining superiority through Day 28.

Q: What is Credelio Quattro-CA1 and how is it regulated by the FDA?

Credelio Quattro-CA1 is a formulation conditionally approved to treat New World screwworm larvae infestations in dogs. According to Elanco, the FDA granted conditional approval under application 141-619, pending full demonstration of effectiveness, for dogs 8 weeks and older weighing at least 3.3 pounds.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Elanco (NYSE: ELAN) reported new peer-reviewed data showing that Credelio Quattro (lotilaner, moxidectin, praziquantel, pyrantel) achieves significantly faster tick kill than Simparica Trio and NexGard Plus. Against black-legged ticks, Credelio Quattro was the only product to reach significant reduction within 8 hours, maintaining this speed through Day 28 of the monthly dosing period.

Lotilaner also provided the fastest initial kill of lone star ticks in 12 hours versus sarolaner and afoxolaner and sustained superiority throughout the interval. Credelio Quattro carries an FDA-approved claim for prevention of Lyme disease in dogs via killing black-legged ticks and is indicated for multiple internal and external parasites, with detailed safety warnings for neurologic and gastrointestinal adverse events.

Positive

8-hour black-legged tick kill maintained to Day 28 versus 12–24 hours for competitors
Fastest initial lone star tick kill in 12 hours, sustained through dosing interval
FDA-approved Lyme disease prevention claim in dogs via killing black-legged ticks
Broad indications including heartworm prevention and treatment/control of fleas, ticks, roundworms, hookworms, and tapeworms
Peer-reviewed head-to-head studies in Parasites & Vectors (2024, 2026) supporting comparative speed-of-kill claims
Conditional FDA approval of Credelio Quattro-CA1 for New World screwworm larvae treatment

Negative

Isoxazoline-class neurologic risks, including tremors, incoordination, and seizures, especially in predisposed dogs
Gastrointestinal adverse reactions such as vomiting and diarrhea reported in Credelio Quattro trials
Credelio Quattro not effective against adult heartworms; dogs must be tested for existing infections before use
Safety not evaluated in breeding, pregnant, or lactating dogs for Credelio and Credelio Quattro
Credelio Quattro-CA1 only conditionally approved pending full demonstration of effectiveness (FDA application 141-619)

News Market Reaction – ELAN

-0.55%

1 alert

-0.55% Session close to close

-3.6% Trough Tracked

$12.73B Market Cap

0.0x Rel. Volume

In the Jul 22 session, ELAN declined 0.55%, reflecting a mild negative market reaction. Argus tracked a trough of -3.6% from its starting point during tracking.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Recent insider activity was labeled Net Buying, with 9,882 shares bought and 0 sold. That context ac...

Analysis

Recent insider activity was labeled Net Buying, with 9,882 shares bought and 0 sold. That context accompanies the tick-kill findings, while disclosed neurologic adverse-reaction risks remain relevant to product adoption.

Key Figures

Black-legged tick reduction: 8 hours Lone star tick kill: 12 hours Day 28 speed of kill: 8 hours +5 more

8 metrics

Black-legged tick reduction 8 hours Credelio Quattro after infestation

Lone star tick kill 12 hours Lotilaner initial speed of kill

Day 28 speed of kill 8 hours Credelio Quattro against black-legged ticks

Competitor Day 28 timing 12 hours and 24 hours Simparica Trio and NexGard Plus, respectively

Lyme disease transmission timing 24-48 hours Typically occurs after tick attachment

Statistical significance threshold P<0.05 Tick-count evaluation tables

Study evaluation time points 4, 8, 12, 24, and 48 hours Post-treatment and reinfestation evaluation

Lone star tick Day 28 timing 8 hours Lotilaner speed of kill

Historical Context

5 past events · Latest: Jul 08 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 08	earnings scheduling notice	Neutral	+0.2%	Company scheduled second-quarter 2026 results release and investor conference call.
Jun 18	venture platform launch	Positive	+3.5%	Elanco announced a $25 million multi-year commitment for animal-health innovation investments.
Jun 15	vaccine approval	Positive	+0.5%	USDA approved TruCan Ultra Lyme-L4 combination vaccine for dogs.
Jun 04	screwworm response	Positive	+0.6%	Elanco outlined support for producers and pet owners confronting New World screwworm.
Jun 03	consumer research release	Positive	+4.0%	Company reported pet-health spending remained resilient despite rising living costs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

ELAN's five recent news events were followed by positive 24-hour price reactions, ranging from 0.2% to 3.98%.

Key Terms

endectocides, isoxazoline, borrelia burgdorferi, alpha-gal syndrome

4 terms

endectocides medical

"Comparative speed of kill of induced Ixodes scapularis infestations"

Drugs that simultaneously target internal parasites (like worms) and external parasites (like ticks or lice), often used in veterinary and sometimes human medicine; they act as a two-in-one treatment to reduce parasite loads across an animal or population. Investors watch endectocides because they can create broad commercial demand, affect product pipelines and regulatory reviews, and influence sales and margins in companies that make treatments for livestock, pets, or public-health programs—similar to a combined household product that replaces two separate purchases.

isoxazoline medical

"Lotilaner, an ingredient in Credelio Quattro, belongs to the isoxazoline class"

A class of synthetic chemicals used as active ingredients in parasite-control products, isoxazolines work by disrupting the nervous system of fleas, ticks and other parasites, causing paralysis and death. Like a key that jams a pest’s nerve signals, they are widely used in veterinary medicines and some animal health products. Investors track isoxazoline-related drugs because their safety, patents, regulatory approvals and market acceptance affect sales, recurring revenue and competitive positioning in the pet and animal health market.

borrelia burgdorferi medical

"The black-legged tick is the primary vector for Borrelia burgdorferi"

Borrelia burgdorferi is the bacterium that causes Lyme disease, transmitted to humans through certain tick bites. Think of it as a stealthy invader that can trigger long-lasting symptoms and spur demand for diagnostics, antibiotics, and potential vaccines; outbreaks or changing case patterns can affect healthcare spending, regulatory attention, and the prospects of biotech and medical-device companies working on testing or treatments, making it material to investors tracking those sectors.

alpha-gal syndrome medical

"best known for its association with alpha-gal syndrome"

A delayed allergic condition caused by an immune reaction to a carbohydrate called alpha-gal, usually triggered after certain tick bites; people with the condition develop hives, stomach upset, or in severe cases, anaphylaxis several hours after eating mammal meat and some related products. It matters to investors because it creates demand for diagnostic tests, treatments, and alternative food products, and can affect regulatory approvals, insurance claims, and market size estimates for companies working on related healthcare or food-sector solutions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

07/22/2026 - 06:27 AM

Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro:

Kills existing black-legged tick (Ixodes scapularis) infestations faster² than leading competitors, within just 8 hours of treatment.ⁱ
Kills the lone star tick (Amblyomma americanum) within 12 hours of infestation; achieving the fastest³ initial speed of tick kill compared to the competition.ⁱⁱ
Achieves a rapid speed of kill⁴ on Day 0 and on Day 28, with no statistically significant drop-off in performance at the end of the dosing period.^i,ii
Outlasts competitors whose speed of kill^2,4 performance declined at the end of the month.^i,ii

INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- When it comes to killing ticks, veterinarians and pet owners want it done fast. New data published in Parasites & Vectors, a leading peer-reviewed publication, demonstrates that Elanco Animal Health's (NYSE: ELAN) Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) kills ticks¹ faster² than leading competitors Simparica Trio^® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard^® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets).ⁱ

Newly Published Data Found Credelio Quattro:

Faster² Tick¹ Speed of Kill: Credelio Quattro is the only product proven to significantly reduce black-legged ticks within 8 hours.ⁱ Lotilaner, the active ingredient in Credelio Quattro also has the fastest initial tick speed of kill against the lone star tick - in just 12 hours – and sustains the advantage throughout the dosing interval.ⁱⁱ
Outperforms the Competition: Outperforms Simparica Trio^® (12 hours) and NexGard^® Plus (24 hours) at the end of the dosing period (Day 28).ⁱ
Consistency Over Competitors: Achieves 8-hour speed of kill¹ on Day 0 and on Day 28 with no performance drop-off. Rapid kill is critical for preventing Lyme disease transmission, which typically occurs 24-48 hours after attachment.ⁱ

"Speed of kill is a critical factor for veterinarians and pet owners when choosing parasite coverage because the longer a tick is attached, the more likely it is to transmit dangerous diseases, like Lyme disease, to pets," said Dr. Casey Locklear, veterinarian and leading parasiticides expert at Elanco. "These results reinforce that lotilaner, the active ingredient in Credelio Quattro, not only starts working fast but maintains its speed of kill⁴ against multiple species of ticks⁵, providing veterinarians and pet owners with the confidence that their dogs are protected from the very start of the month to the very end."

The black-legged tick is the primary vector for Borrelia burgdorferi, the bacterium responsible for Lyme disease and anaplasmosis. The study, which evaluated the speed of kill against Ixodes scapularis (black-legged tick), found that Credelio Quattro was the only product tested to achieve significant initial tick reduction² within just 8 hours of infestation. Notably, this rapid speed of kill¹ was maintained from the beginning of the month through Day 28, providing consistent protection for the entire dosing interval.ⁱ

"Ticks are on the move. They are no longer limited to the places or seasons where we have historically expected to find them," said Dr. Kathryn Reif, Bailey-Goodwin Endowed Associate Professor in Parasitology at Auburn University. "As their geographic range expands, so does the risk of tick bites and exposure to the pathogens they carry. Because tick-borne diseases can threaten the health of people, pets, and livestock, raising public awareness is more important than ever as tick populations grow and spread into new regions."

The findings are based on evaluation time points at 4, 8, 12, 24, and 48 hours post-treatment and reinfestation. The data demonstrates that Credelio Quattro outperforms Simparica Trio and NexGard Plus in rapid tick¹ reduction, particularly in the critical first 8 to 12 hours.ⁱ

Speed of kill against Ixodes scapularis (black-legged tick)^ ⁱ
Time point at which active achieved consistent superior efficacy vs. untreated control group^¥
Day of Study	Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel)	Simparica Trio (sarolaner, moxidectin and pyrantel)	NexGard Plus (afoxolaner, moxidectin, and pyrantel)
0	8 hrs	12 hrs	12 hrs
21	8 hrs	24 hrs	24 hrs
28	8 hrs	12 hrs	24 hrs
^Tick counts were evaluated at all 4-, 8-, 12-, 24-, and 48-hour time points as part of the study design ^¥P<0.05.

Credelio Quattro also has a U.S. Food and Drug Administration approved claim for prevention of Lyme disease in dogs as a direct result of killing black-legged ticks.

Does Credelio Quattro Kill the Lone Star Tick?

Credelio Quattro is approved to protect dogs from the lone star tick (Amblyomma americanum), and its active ingredient, lotilaner, also has the fastest³ initial speed of tick kill against the lone star tick – in just 12 hours – and sustains that advantage throughout the dosing interval.ⁱⁱ This aggressive and expanding tick species – established across the South, Midwest and Northeast, and continuing to spread – is one of the hardest to kill and is best known for its association with alpha-gal syndrome, or the red meat allergy in humans. It can also transmit dangerous disease-causing pathogens to dogs.ⁱⁱⁱ A 2024 head-to-head study published in Parasites & Vectors compared lotilaner, the active ingredient in Credelio (lotilaner) and Credelio Quattro with sarolaner in Simparica Trio and afoxolaner in NexGard^®, and found that lotilaner kills the lone star tick faster⁴ than sarolaner in Simparica Trio and afoxolaner in NexGard, protecting dogs against this pathogen-carrying tick.

Speed of kill against Amblyomma americanum (lone star tick)^ ⁱⁱ
Time point at which active achieved consistent superior efficacy vs. untreated control group^¥
Day of Study	Credelio (lotilaner)	Sarolaner (sarolaner, moxidectin and pyrantel)	NexGard (afoxolaner)
0	12 hrs	24 hrs	24 hrs
21	12 hrs	48 hrs	48 hrs
28	8 hrs	48 hrs	72 hrs
^Tick counts were evaluated at all 4-, 8-, 12-, 24-, 48-, and 72-hour time points as part of the study design ^¥P<0.05.

"With a heavier tick season and emergency room visits from tick bites on the rise^iv, pet owners should remain vigilant and keep their pets on year-round parasite coverage," Dr. Locklear notes. "We continue to look for opportunities to make parasite protection stronger and evolve research around best-in-class medicines."

Frequently Asked Questions About Ticks and Credelio Quattro:

How fast does Credelio Quattro kill ticks?

Studies show that lotilaner, the active ingredient in Credelio Quattro kills ticks⁵ faster⁶ than the competition.^i,ii A 2026 study published in Parasites & Vectors shows that Credelio Quattro achieved significant reduction² of black-legged ticks within 8 hours of infestation.ⁱ A 2024 study shows that lotilaner, the active ingredient in Credelio and Credelio Quattro also has the fastest³initial speed of tick kill against the lone star tick – in just 12 hours – and sustains that advantage throughout the dosing interval.ⁱⁱ

Why is it important to kill ticks quickly?

The risk of disease transmission increases the longer a tick remains attached, making rapid speed of kill a critical factor in preventing the transmission of disease. A 2026 study shows that Credelio Quattro was the only product tested that significantly reduced² black-legged ticks within 8 hours.ⁱ

Does Credelio Quattro lose effectiveness to kill ticks¹ quickly at the end of the month?

No. The data shows that Credelio Quattro maintains its 8-hour speed of kill² on Day 28, whereas competitors showed a decline in performance.ⁱ

Are black-legged ticks linked to the red meat allergy in humans?

In the United States, alpha-gal syndrome, or red meat allergy, is usually associated with bites from the lone star tick (Amblyomma americanum); however, two Emerging Infectious Diseases studies link bites from black-legged ticks (deer ticks) and western black-legged ticks to potentially life-threatening alpha-gal syndrome.^v Additional work will be needed to determine a possible link, according to the researchers, but this continues to put emphasis on the need for tick bite protection for humans.

To learn more about Credelio Quattro visit CredelioQuattroVet.com.

PM-US-26-1188

Ixodes scapularis (black-legged tick)
Based on the time to statistical significance vs. control in a head-to-head study on Day 0 post-treatment and Day 28 for reinfestations comparing Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard Plus (afoxolaner, moxidectin, and pyrantel) against Ixodes scapularis.
Based on the time to statistical significance vs. control in a head-to-head study comparing Credelio (lotilaner)—not Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard (afoxolaner).
Based on the time to statistical significance vs control in two separate head-to-head studies. The first study compared Credelio (lotilaner)—not Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard (afoxolaner) against Amblyomma americanum. The second study compared Credelio Quattro, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio (sarolaner, moxidectin, and pyrantel) and NexGard Plus (afoxolaner, moxidectin, and pyrantel) against I. scapularis.
Ixodes scapularis (black-legged tick) and Amblyomma americanum (lone star tick)

NexGard and NexGard Plus are registered trademarks of Boehringer Ingelheim Animal Health USA Inc. Simparica Trio is a registered trademark of Zoetis Services LLC.

Credelio Quattro, Credelio, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Other company and product names are trademarks of their respective owners. © 2026 Elanco or its affiliates

ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

Indications for Credelio Quattro/Credelio Quattro-CA1

Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm, and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater. Credelio Quattro is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

Credelio Quattro-CA1 is conditionally approved for the treatment of infestations caused by New World screwworm (NWS) larvae in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.

Important Safety Information for Credelio Quattro/Credelio Quattro-CA1

Lotilaner, an ingredient in Credelio Quattro/Credelio Quattro-CA1, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, incoordination, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro/Credelio Quattro-CA1 administration as it is not effective against adult heartworms. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.

Credelio Quattro-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-619. If you suspect that your dog is infested with NWS larvae, seek veterinary care immediately for treatment to include removal of larvae and appropriate wound care.

For complete safety information, please see the Credelio Quattro/Credelio Quattro-CA1 product label or ask your veterinarian.

Indications for Credelio
Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, brown dog tick, and longhorned tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. Credelio is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

Important Safety Information for Credelio
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian.

ⁱ Reif, K.E., Kollasch, T.M., Locklear, C.L. et al. Comparative speed of kill of induced Ixodes scapularis infestations following treatment of dogs with endectocides containing either sarolaner (Simparica Trio™), afoxolaner (NexGard^® PLUS), or lotilaner (Credelio Quattro™). Parasites Vectors (2026). https://doi.org/10.1186/s13071-026-07559-yⁱⁱ Reif KE, Kollasch TM, Neilson JC, Herrin BH, Ryan WG, Bell MC, Beltz MS, Dryden MW, Jesudoss Chelladurai JRJ, Miller KR, Sutherland CJ. Comparative speed of kill provided by lotilaner (Credelio™), sarolaner (Simparica Trio™), and afoxolaner (NexGard™) to control Amblyomma americanum infestations on dogs. Parasite Vectors. 2024 Jul 20;17(1):313.
ⁱⁱⁱ Centers for Disease Control and Prevention. (n.d.). Where Ticks Live. Centers for Disease Control and Prevention. Retrieved August 8, 2024, from https://www.cdc.gov/ticks/about/where-ticks-live.html
^iv CDC Data Show Weekly ER Visits for Tick Bites Higher Than Usual." Centers for Disease Control and Prevention, 23 Apr. 2026,
^v Van Beusekom, Mary. "Research Ties Bites from 2 More Types of Ticks to Red Meat Allergy." CIDRAP (Center for Infectious Disease Research and Policy), 4 Apr. 2025

Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com
Media Contact: Season Solorio (765) 316-0233 season.solorio@elancoah.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/credelio-quattro-lotilaner-moxidectin-praziquantel-and-pyrantel-chewable-tablets-kills-ticks-faster-than-simparica-trio-sarolaner-moxidectin-and-pyrantel-chewable-tablets-and-nexgard-plus-afoxolaner-moxidectin-and-302831444.html

SOURCE Elanco Animal Health

FAQ

What did Elanco (NYSE: ELAN) announce about Credelio Quattro on July 22, 2026?